SHRED - Retatrutide
20mg
$299.95
Skip to product information
SHRED - Retatrutide
$299.95
RESEARCH PURPOSES ONLY
Used solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans.
- Administered to humans as part of an experiment or investigation.
- Supplied to another party for human investigational use.
PRODUCT DESCRIPTION
Shred — Retatrutide | 10mg, 20mg, 30mg | ≥99% Purity | Research-Grade
The first and only triple hormone receptor agonist developed to date. Retatrutide (LY3437943) simultaneously targets GLP-1, GIP, and glucagon receptor pathways. No other compound in the current research pipeline activates all three. Phase 2 clinical trial data published in the New England Journal of Medicine reported up to 24% body weight reduction in participants over 48 weeks, alongside notable changes across multiple metabolic biomarkers. It has been the subject of significant clinical investigation, with researchers describing its triple-receptor mechanism as a potential step change in the field.
Published research has investigated its role in:
- Triple-agonist activity across GLP-1, GIP, and glucagon receptor pathways
- Significant reductions in body weight observed in clinical trial settings (up to 24% in 48-week Phase 2 trials)
- Appetite regulation, glycaemic control, and energy expenditure modulation
- Improvements in metabolic biomarkers including HbA1c, fasting glucose, and lipid profiles
Retatrutide represents one of the most studied next-generation incretin-based compounds, with its first-in-class triple-receptor mechanism distinguishing it from single and dual agonist peptides currently under investigation.
TECHNICAL SPECIFICATIONS
SHIPPING & RETURNS
Free express shipping on orders over $200.
We do not accept returns due to the sensitive nature of research compounds. Damaged or defective items must be reported within 24 hours of delivery with photos. See our full Shipping Policy and Refund Policy for details.
Quick facts
- Compound: Retatrutide (LY3437943)
- Classification: Triple GLP-1 / GIP / glucagon receptor agonist
- Vial sizes: 10mg, 20mg, 30mg
- Purity: ≥99% (HPLC-tested)
- Research area: Metabolic, incretin, and glucagon receptor pharmacology
- Storage (lyophilised): −20°C, light-protected
- Storage (reconstituted): 2–8°C, use per COA window
- Dispatch: Same-day from Australian warehouse
- Use: In-vitro and laboratory research only
Research notes
Often studied with
- Bronzed (Melanotan II) — melanocortin receptor research
- The Comedown (Glutathione) — antioxidant pairing
Research use only. Not TGA-approved. Not for human consumption. Buyers must be 18+ and acknowledge they are conducting legitimate research.
LABORATORY-GRADE PEPTIDES
B.A.B.E LABS supplies high-purity peptide compounds intended for laboratory research and analytical investigation. Our focus is on compound integrity, consistency, and controlled preparation to support experimental protocols.
You may also like
PRODUCT DISCLAIMER
This product is manufactured in a GMP-compliant facility and guaranteed ≥99% purity. Every batch is analytically verified by RP-HPLC and accompanied by a Certificate of Analysis. All batches are free of LPS. This product is intended strictly as a research chemical, for scientific research and educational purposes only. It is not intended for human or animal consumption and has not been evaluated or approved by the TGA or any regulatory authority for therapeutic, medical, or cosmetic use. By completing your purchase, you acknowledge that this compound is an investigational chemical and agree to use it solely for legitimate research purposes in accordance with all applicable laws and regulations.